Flyte Secures $2.68M Seed Round
Summary
EAGAN, MN, Pelvital is pleased to announce the successful closing of a $2.68 million seed funding round for Flyte. Pelvital, a leading innovator in womens health, is pleased to announce the successful closing of a $2.68 million seed funding round for Flyte, a revolutionary, accessible, and clinically proven treatment for stress urinary incontinence (SUI) and weakened pelvic floor muscles. This funding milestone emphasizes Flytes significant impact in addressing an underserved health concern among women. Flyte is the only at-home intravaginal device that delivers the proven treatment modality of mechanotherapy to treat SUI and strengthen pelvic floor muscles quickly and effectively. Their first product, Flyte®, is an FDA-cleared novel in-home treatment for stress urinary incontinence and weakened pelvic floor muscles.